The Catalan pharmaceutical company Reig Jofre closed 2025 with a net profit of €4.99 million, 52% less than the previous year due to temporary production shutdowns and a 30% drop in antibiotic sales. In total, the majority family-owned group obtained revenues of €331.1 million, 2% less than in 2024. The year was marked by the company's industrial transformation. At the Toledo plant, planned shutdowns and the renovation of two antibiotic production lines were carried out in a context of recovering demand for oral antibiotics after the exceptional increases during the pandemic. Investments in the sterile area continued at the Barcelona plant. The company also integrated Leanbioand, therefore, Syna Therapeutics, which they had previously formed jointly.

The Catalan pharmaceutical company Reig Jofre has increased its stake in the biotechnology firm Leanbio from 47% to 85%, after acquiring shares from current partners for €3.5 million, as reported Tuesday to the Spanish National Securities Market Commission (CNMV). The remaining 15% of Leanbio's capital remains in the hands of the founding team and specialized shareholders, all committed to boosting the Spanish biotechnology ecosystem. This transaction represents a decisive strategic step in the evolution of Reig Jofre's business model, expanding its activity "towards a biopharmaceutical structure capable of encompassing the phases of research, design, process development, industrial production, and scale-up of biotechnological medicines." The increased stake in Leanbio, founded in 2014 by Dr. Andreu Soldevila and Albert Font, was achieved through the purchase of shares from existing partners. The integration is based on an alliance initiated in 2018 with the creation of the joint venture Syne Therapeutics, a 50/50 joint venture between the two parties for the development of biosimilars, and the subsequent acquisition of an additional 10% stake in Leanbio by Reig Jofre.

Reig Jofre, a Catalan family-owned pharmaceutical company, earned €10.5 million last year, 11% more than the previous year, and posted revenues of €337 million, up 7%, driven by a strong external push, as almost €60 out of every €100 were generated abroad. This week, it inaugurated an expansion that doubles the production capacity of its Swedish subsidiary, Bioglan. And in 2025, it celebrated its first decade on the stock market, since its merger with the former Natraceutical. The listing, which has led to around 6,000 shareholders today, has been a positive experience, according to its CEO, Ignasi Biosca, representing the third generation of owners of the company, who receivesCompanies at its Sant Joan Despí plant, where they produce high-precision anesthetics for the Japanese market. The fact is that the stock market, he adds, has been a way to reinforce the group's commitment to innovation, especially technological innovation, and also to boost its shift from traditional chemical-based medicines to biotechnology-based medicines, which offer greater flexibility, compared to prescription drugs, which, after years of public pressure to lower their prices, are reported to be selling more than they are producing.

Reig Jofre has doubled the production capacity of its Swedish subsidiary, Bioglan, located in the city of Malmö. This action allows for the expansion of the Yggdrasil production line and "represents a key step in the global supply of an innovative therapy for patients with advanced Parkinson's disease," according to group sources. The plant specializes in semi-solid products for the pharmaceutical and medical technology industries.

Reig Jofre, the majority-family Catalan pharmaceutical company, warned this Wednesday of the potential effects of the proposed pharmaceutical law approved by the Spanish government. While stating that the tariffs imposed by the United States, where pharmaceutical products have not yet been taxed, will not affect it much because it only sells between 1% and 2% of its production, the company's CEO, Ignasi Biosca, warned of the potential effects of these taxes.